Redhill Biopharma (Redhill Biopharma) Receivables Turnover : 0.37 (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Redhill Biopharma's Revenue for the three months ended in Jun. 2023 was $1.80 Mil. Redhill Biopharma's average Accounts Receivable for the three months ended in Jun. 2023 was $4.88 Mil. Hence, Redhill Biopharma's Receivables Turnover for the three months ended in Jun. 2023 was 0.37.

Redhill Biopharma Receivables Turnover Historical Data

The historical data trend for Redhill Biopharma's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Receivables Turnover Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

5.79

4.31

2.84

1.87

0.35

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															0.50	0.36	0.17	0.37	-

Competitive Comparison of Redhill Biopharma's Receivables Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redhill Biopharma's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Receivables Turnover falls into.

Redhill Biopharma Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Redhill Biopharma's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	6.53	/ (	(34.521	+	2.591)	/	2 )
=	6.53	/	18.556
=	0.35

Redhill Biopharma's Receivables Turnover for the quarter that ended in Jun. 2023 is calculated as

	Receivables Turnover (Q: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2023 )	/ (	(Accounts Receivable (Q: Mar. 2023 )	+	Accounts Receivable (Q: Jun. 2023 ))	/	count )
=	1.796	/ (	(6.854	+	2.903)	/	2 )
=	1.796	/	4.8785
=	0.37

Redhill Biopharma (NAS:RDHL) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Redhill Biopharma Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.